AR089666A1 - STABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION INCLUDING LEVOCETIRIZINE OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT, AND MONTELUKAST OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT - Google Patents

STABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION INCLUDING LEVOCETIRIZINE OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT, AND MONTELUKAST OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT

Info

Publication number
AR089666A1
AR089666A1 ARP130100039A ARP130100039A AR089666A1 AR 089666 A1 AR089666 A1 AR 089666A1 AR P130100039 A ARP130100039 A AR P130100039A AR P130100039 A ARP130100039 A AR P130100039A AR 089666 A1 AR089666 A1 AR 089666A1
Authority
AR
Argentina
Prior art keywords
acceptable salts
pharmaceutical
viewpoint
montelukast
oral administration
Prior art date
Application number
ARP130100039A
Other languages
Spanish (es)
Inventor
Ho Kim Dong
Soo Kim Kyeong
Il Kim Yong
Hyun Park Jae
Soo Woo Jong
Kwan Kwon Taek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745292&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089666(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of AR089666A1 publication Critical patent/AR089666A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

La presente se refiere a una formulación farmacéutica para administración oral para prevenir o tratar la rinitis alérgica o el asma, que comprende: (a) una primera parte de partículas que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmacéutico y un ácido orgánico; y (b) una segunda parte de partículas que comprende montelukast o una de sus sales aceptables desde el punto de vista farmacéutico. La formulación farmacéutica de acuerdo con la presente comprende un ácido orgánico como agente estabilizador, que puede inhibir en forma efectiva la producción de levocetirizina y sustancias relacionadas con montelukast, y de este modo, muestran buena estabilidad.This refers to a pharmaceutical formulation for oral administration to prevent or treat allergic rhinitis or asthma, comprising: (a) a first part of particles comprising levocetirizine or a pharmaceutically acceptable salt thereof and a organic acid; and (b) a second part of particles comprising montelukast or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention comprises an organic acid as a stabilizing agent, which can effectively inhibit the production of levocetirizine and substances related to montelukast, and thus, show good stability.

ARP130100039A 2012-01-06 2013-01-04 STABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION INCLUDING LEVOCETIRIZINE OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT, AND MONTELUKAST OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT AR089666A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120001954A KR101418404B1 (en) 2012-01-06 2012-01-06 Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof

Publications (1)

Publication Number Publication Date
AR089666A1 true AR089666A1 (en) 2014-09-10

Family

ID=48745292

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100039A AR089666A1 (en) 2012-01-06 2013-01-04 STABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION INCLUDING LEVOCETIRIZINE OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT, AND MONTELUKAST OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT

Country Status (21)

Country Link
US (1) US9486528B2 (en)
EP (1) EP2800558B1 (en)
JP (1) JP6163165B2 (en)
KR (1) KR101418404B1 (en)
CN (1) CN104039314B (en)
AR (1) AR089666A1 (en)
BR (1) BR112014016472B1 (en)
ES (1) ES2671428T3 (en)
HK (1) HK1200337A1 (en)
JO (1) JO3388B1 (en)
MX (1) MX354073B (en)
PH (1) PH12014501545A1 (en)
PL (1) PL2800558T3 (en)
PT (1) PT2800558T (en)
RU (1) RU2614382C2 (en)
SG (1) SG11201403811VA (en)
SI (1) SI2800558T1 (en)
TR (1) TR201807978T4 (en)
TW (1) TWI565482B (en)
WO (1) WO2013103262A1 (en)
ZA (1) ZA201405756B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717684B2 (en) 2014-04-25 2017-08-01 R.P. Scherer Technologies, Llc Stable montelukast solution
KR101669556B1 (en) * 2014-07-02 2016-10-28 한미약품 주식회사 Liquid Formulation of Montelukast or Pharmaceutically Acceptable Salt Thereof for Oral Administration
JP6575031B2 (en) * 2014-07-28 2019-09-18 日本ケミファ株式会社 Montelukast sodium preparation
RU2580303C1 (en) * 2015-02-18 2016-04-10 Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" Composition of pellet drug with proroxanum active ingredient
PL3222279T3 (en) 2016-03-21 2022-05-09 Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością Oral pharmaceutical formulation of montelukast and levocetirizine and method for its production
KR102481517B1 (en) * 2021-08-30 2022-12-27 주식회사 클라시아 Pharmaceutical Formulation
WO2023068839A1 (en) * 2021-10-21 2023-04-27 한화제약주식회사 Film-coated tablet with improved stability containing montelukast or pharmaceutically acceptable salt thereof and levocetirizine or pharmaceutically acceptable salt thereof
KR20240045586A (en) 2022-09-30 2024-04-08 주식회사 제뉴원사이언스 Bilayer tablets with enhanced stability comprising levocetirizine or pharmaceutically acceptable salt thereof and montelukast or pharmaceutically acceptable salt thereof and method for preparing the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1204580A (en) 1968-10-05 1970-09-09 Aspro Nicholas Ltd Pharmaceutical dosage forms
NO155805C (en) 1981-02-06 1987-06-10 Ucb Sa ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVITY 2- (4- (DIPHENYLMETHYL) -1-PIPERAZINYL) -ACDIC ACIDS AND THEIR AMIDS AND NON-TOXIC SALTS.
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
GB8827390D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
GB8827391D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
DE4209824A1 (en) 1991-09-06 1993-03-11 Schaeffler Waelzlager Kg ROLLER BEARING FOR LINEAR MOVEMENTS
GB9305282D0 (en) 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine
BE1010094A3 (en) 1996-04-10 1997-12-02 Ucb Sa NEW [2- (1-piperazinyl) ethoxy] SUBSTITUTED.
BE1010095A3 (en) 1996-04-10 1997-12-02 Ucb Sa METHOD OF PREPARATION OF ACID 2- [2- [4 - [(4-Chlorophenyl) phenylmethyl] -1-PIPERAZINYL] ETHOXY] acetic acid AND ITS SALTS.
DE10007203A1 (en) * 2000-02-17 2001-08-23 Asta Medica Ag Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist
AU2001250206A1 (en) 2000-04-12 2001-10-30 Merck Frosst Canada Ltd Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
KR100795419B1 (en) 2006-01-03 2008-01-17 (주)네오메딕스 Pharmaceutical formulation containing amlodipine and aspirin
KR100910848B1 (en) * 2007-09-13 2009-08-06 재단법인서울대학교산학협력재단 Microsphere for nasal spray comprising drug for treating allergic rhinitis and preparation method thereof
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
KR20130009553A (en) 2011-07-15 2013-01-23 한미약품 주식회사 Capsule formulation comprising montelukast or a pharmaceutically acceptable salt thereof, and levocetirizine or a pharmaceutically acceptable salt thereof
KR101861307B1 (en) * 2011-10-13 2018-07-06 한미약품 주식회사 Composite formulation comprising a tablet encapsulated in a hard capsule

Also Published As

Publication number Publication date
MX354073B (en) 2018-02-12
KR20130081013A (en) 2013-07-16
RU2614382C2 (en) 2017-03-24
ZA201405756B (en) 2016-08-31
US9486528B2 (en) 2016-11-08
JP6163165B2 (en) 2017-07-12
CN104039314A (en) 2014-09-10
SG11201403811VA (en) 2014-08-28
BR112014016472A8 (en) 2017-07-04
ES2671428T3 (en) 2018-06-06
TR201807978T4 (en) 2018-06-21
BR112014016472A2 (en) 2017-06-13
SI2800558T1 (en) 2018-06-29
WO2013103262A1 (en) 2013-07-11
KR101418404B1 (en) 2014-07-10
PH12014501545B1 (en) 2014-10-08
EP2800558A1 (en) 2014-11-12
EP2800558A4 (en) 2015-08-12
PL2800558T3 (en) 2018-08-31
TW201332590A (en) 2013-08-16
TWI565482B (en) 2017-01-11
US20140356422A1 (en) 2014-12-04
RU2014132428A (en) 2016-02-27
BR112014016472B1 (en) 2022-03-15
HK1200337A1 (en) 2015-08-07
JP2015503579A (en) 2015-02-02
JO3388B1 (en) 2019-03-13
PH12014501545A1 (en) 2014-10-08
EP2800558B1 (en) 2018-04-11
MX2014008059A (en) 2014-10-06
CN104039314B (en) 2017-07-14
PT2800558T (en) 2018-06-05

Similar Documents

Publication Publication Date Title
AR089666A1 (en) STABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION INCLUDING LEVOCETIRIZINE OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT, AND MONTELUKAST OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
DOP2016000175A (en) (2S) -N - [(1S) -1-CIANO-2-FENILETIL] -1,4-OXAZEPAN-2-CARBOXAMIDS AS INHIBITORS OF DIPEPTIDIL PEPTIDASE 1
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
BR112014026493A2 (en) imidazotiadiazole derivatives as protease activated receptor 4 (par4) inhibitors to treat platelet aggregation
AR088382A1 (en) FORMULATIONS OF ETANERCEPT STABILIZED WITH XILITOL
MX2015010971A (en) Novel pyrazole derivative.
NZ725008A (en) Compounds for treating spinal muscular atrophy
BR112014026643A8 (en) imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for the treatment of platelet aggregation, their uses and pharmaceutical composition
NZ631100A (en) Soft chewable pharmaceutical products
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
BR112018006922A2 (en) camptothecin stabilizing pharmaceutical compositions
MX2015016425A (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease.
MX2015010829A (en) Therapeutic compounds and uses thereof.
IN2014DN06869A (en)
BR112016026552A8 (en) carboxamide derivatives, their uses, pharmaceutical composition, and combination
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
MX2016014946A (en) Carboxamide derivatives.
UY33723A (en) ? COMPOUNDS AND ITS USE FOR TREATMENT OF DISEASES RELATED TO Aß ?.
BR112015025058A2 (en) pharmaceutical composition capable of easily controlling the dissolution pattern of lacosamide or a pharmaceutically acceptable salt thereof
MX2016006667A (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors.
BR112016023991A2 (en) polycyclic herg activators
BR112016029417A2 (en) stabilized desmopressin
BR112017010841A2 (en) formulations of a pi3k / mtor inhibitor for intravenous administration
PH12016502247A1 (en) Carboxamide derivatives

Legal Events

Date Code Title Description
FC Refusal